



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



FPR2 agonist 2

Cat. No.:	HY-144604
CAS No.:	2829263-20-7
Molecular Formula:	C ₂₅ H ₂₀ F ₂ N ₄ O ₂
Molecular Weight:	446.45
Target:	Others
Pathway:	Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (111.99 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.2399 mL	11.1995 mL	22.3989 mL
	5 mM		0.4480 mL	2.2399 mL	4.4798 mL
	10 mM		0.2240 mL	1.1199 mL	2.2399 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

FPR2 agonist 2 is a potent and permeates the blood–brain barrier FPR2 agonist with an EC₅₀ of 0.13 μM, 1.1 μM for FPR2 and FPR1, respectively. FPR2 agonist 2 inhibits the production of pro-inflammatory cytokines, counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity^[1].

IC₅₀ & Target

EC₅₀: 0.13 μM (FPR2); 1.1 μM (FPR1)^[1]

In Vitro

FPR2 agonist 2 (compound (S)-11l) (1-100 μM; 48 h) exhibits low cytotoxicity with an EC₅₀ value of 20.8 μM in N9 cells^[1]. FPR2 agonist 2 (FPR1/FPR2 HL60 cells) shows agonist activity with EC₅₀s of 0.13 μM, 1.1 μM (IC₅₀s of 0.085 μM, Not determined) for FPR2 and FPR1, respectively^[1]. FPR2 agonist 2 (0.1 μM) effectively blocks LPS-induced cell death and NO production and effectively suppresses the effect of LPS stimulation^[1]. FPR2 agonist 2 (0.1 μM) counterbalances the changes in mitochondrial function, and inhibits caspase-3 activity^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1]

	Cell Line:	N9 cells
	Concentration:	1-100 μ M
	Incubation Time:	48 h
	Result:	Exhibited low cytotoxicity with an EC ₅₀ value of 20.8 μ M in N9 cells.
In Vivo	FPR2 agonist 2 (1 mg/kg for i.v.; 10 mg/kg for i.p.) shows the ability to permeate the blood–brain barrier and to accumulate in the brain ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	25-30 g, male CD-1 mice ^[1]
	Dosage:	
	Administration:	1 mg/kg for i.v.; 10 mg/kg for i.p. (dissolved in 5% DMSO, 10% solutol HS 15, and 85% sterile water)
	Result:	Showed the ability to permeate the blood–brain barrier and to accumulate in the brain.

REFERENCES

[1]. Mastromarino M, et al. Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Ureidopropanamides as Formyl Peptide Receptor 2 (FPR2) Agonists to Target the Resolution of Inflammation in Central Nervous System Disorders. J Med Chem. 2022; 65(6):5004-5028.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA